Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study

Biemans Vince B. C.; van der Meulen-de Jong Andrea E.; van der Woude Christine J.; Lowenberg Mark; Dijkstra Gerard; Oldenburg Bas; de Boer Nanne K. H.; van der Marel Sander; Bodelier Alexander G. L.; Jansen Jeroen M.; Haans Jeoffrey J. L.; Theeuwen Rosaline; de Jong Dirk; Pierik Marie J.; Hoentjen Frank

首页> 外文期刊>Journal of Crohn’s & colitis >Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study

【24h】

Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study

机译：Ustekinumab为克罗恩病：ICC登记处的结果，全国范围内观察队列研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background and Aims: Ustekinumab is approved for the treatment of Crohn's disease [CD]. Systematically registered prospective real-world data are scarce. We therefore aimed to study the effectiveness, safety and usage of ustekinumab for CD in everyday practice.

机译：背景和目的：乌司他单抗被批准用于治疗克罗恩病[CD]。系统登记的预期现实世界数据很少。因此，我们旨在研究乌司他单抗治疗CD的有效性、安全性和日常使用情况。

著录项

来源
《Journal of Crohn’s & colitis》 |2020年第1期|共13页
作者
Biemans Vince B. C.; van der Meulen-de Jong Andrea E.; van der Woude Christine J.; Lowenberg Mark; Dijkstra Gerard; Oldenburg Bas; de Boer Nanne K. H.; van der Marel Sander; Bodelier Alexander G. L.; Jansen Jeroen M.; Haans Jeoffrey J. L.; Theeuwen Rosaline; de Jong Dirk; Pierik Marie J.; Hoentjen Frank;
展开▼
作者单位

Radboud Univ Nijmegen Dept Gastroenterol &

Hepatol Med Ctr POB 9101 Code 455 NL-6500 HB;

Leiden Univ Dept Gastroenterol &

Hepatol Med Ctr Leiden Netherlands;

Erasmus MC Dept Gastroenterol &

Hepatol Rotterdam Netherlands;

Univ Amsterdam Acad Med Ctr Dept Gastroenterol &

Hepatol Med Ctr Amsterdam Netherlands;

Univ Med Ctr Groningen Dept Gastroenterol &

Hepatol Groningen Netherlands;

Univ Med Ctr Utrecht Dept Gastroenterol &

Hepatol Utrecht Netherlands;

Vrije Univ Amsterdam Amsterdam Univ Med Ctr Dept Gastroenterol &

Hepatol Amsterdam Netherlands;

Haaglanden Med Ctr Dept Gastroenterol &

Hepatol The Hague Netherlands;

Amphia Hosp Dept Gastroenterol &

Hepatol Breda Netherlands;

Onze Lieve Vrouw Hosp Dept Gastroenterol &

Hepatol Amsterdam Netherlands;

Maastricht Univ Dept Gastroenterol &

Hepatol Med Ctr Maastricht Netherlands;

Leiden Univ Dept Gastroenterol &

Hepatol Med Ctr Leiden Netherlands;

Radboud Univ Nijmegen Dept Gastroenterol &

Hepatol Med Ctr POB 9101 Code 455 NL-6500 HB;

Maastricht Univ Dept Gastroenterol &

Hepatol Med Ctr Maastricht Netherlands;

Radboud Univ Nijmegen Dept Gastroenterol &

Hepatol Med Ctr POB 9101 Code 455 NL-6500 HB;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类杆菌传染病;
关键词
Ustekinumab; Crohn's disease; ICC Registry;

机译：Ustekinumab;克罗恩病;ICC注册处;

相似文献

外文文献
中文文献

1. Comparison of a five-year clinical outcome between Chinese women and men with de novo coronary disease treated with implantation of a drug-eluting stent: a three-center, prospective,registry study [J] . CHEN Shao-liang, YE Fei, ZHANG Jun-ie, 中华医学杂志（英文版） . 2012,第001期
2. Vedolizumab for Inflammatory Bowel Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study ICC Registry - Vedolizumab [J] . Biemans Vince B. C., van der Woude C. Janneke, Dijkstra Gerard, Clinical Pharmacology and Therapeutics . 2020,第5期

机译：Vedolizumab用于炎症性肠病：克罗恩和结肠炎（ICC）登记处的两年结果，全国潜在观察队队伍研究ICC注册表 - Vedolizumab
3. Ustekinumab for Crohn's disease: a nationwide real-life cohort study from Finland (FINUSTE) [J] . Anja Eberl, Taru Hallinen, Gas-Goran af Bjorkesten, Scandinavian journal of gastroenterology. . 2019,第1a12期

机译：Ustekinumab为克罗恩病：来自芬兰（Finuste）的全国真实的队列研究
4. Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study [J] . Ko Yanna, Paramsothy Sudarshan, Yau Yunki, Alimentary pharmacology & therapeutics. . 2021,第3期

机译：优越的治疗持续存在于Ustekinumab在克罗恩病和Vedolizumab中的溃疡性结肠炎与反TNF生物制剂相比：来自持久性澳大利亚国家IBD队列（恐慌）研究的现实世界登记数据
5. Prospective Study of Maternal and Infant Consumption of Probiotic Milk and Allergic Disease: The Norwegian Mother and Child Cohort [C] . Randi Bertelsen, Anne Lise Brantsaeter, Maria Christine Magnus, Annual conference of the International Society of Exposure Science . 2014

机译：幼稚牛奶和过敏性疾病孕产妇和婴幼儿消费的前瞻性研究：挪威母和儿童队列
6. Antibiotic prescribing during infancy and risk of treated obstructive airway diseases during early childhood: A registry-based nationwide cohort study in Denmark [D] . Kinlaw, Alan C. 2016

机译：婴儿期的抗生素处方和幼儿期治疗的阻塞性气道疾病的风险：丹麦一项基于注册表的全国队列研究
7. Ustekinumab for Crohn’s Disease: Results of the ICC Registry a Nationwide Prospective Observational Cohort Study [O] . Vince B C Biemans, Andrea E van der Meulen - de Jong, Christine J van der Woude, -1

机译：Ustekinumab用于克罗恩病：ICC注册中心的结果一项全国性的前瞻性观察队列研究
8. P286 Ustekinumab for Crohn’s Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study [O] . T Straatmijer, V B C Biemans, F Hoentjen, 2021

机译：P286 Ustekuinab为克罗恩病：克罗恩和结肠炎（ICC）登记处的两年结果，全国范围内观察队列研究
9. Potential Utility of Urinary Biomarkers for Risk Prediction in Combat Casualties: A Prospective Observational Cohort Study. [R] . Stewart, I. J., Glass, K. R., Howard, J. T., 2015

机译：尿生物标志物用于战斗伤员风险预测的潜在效用：一项前瞻性观察性队列研究。

Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study

摘要

著录项

相似文献

相关主题

期刊订阅